H
Overview
Henry Meds delivers weight-loss programs through telehealth with licensed providers using a HIPAA-compliant platform called Doxy. Patients complete a medical history and receive a personalized plan that includes medication, delivered without injections or in-person visits. The program combines provider consultations and medication at transparent, upfront pricing with no hidden fees or long-term contracts, emphasizing easy access and affordability. The goal is to make effective weight loss accessible and convenient for a wide audience by offering remote care and included medications.
Work here?Claim your company
Simplify's Take
What believers are saying
- Henry Meds launched oral dissolving tirzepatide tablets in 2026, expanding consumer choice.
- Henry Meds still displays active pricing and programs pages in October 2026.
- Forbes' 2026 review highlighted Henry Meds' user experience and continuing market visibility.
What critics are saying
- Eli Lilly's April 23, 2025 lawsuit targets Henry Meds' personalized tirzepatide marketing.
- FDA's April 1, 2026 guidance tightened compounded tirzepatide rules after shortage removal.
- Compounded oral tirzepatide lacks FDA approval, exposing Henry Meds to efficacy and safety backlash.
What makes Henry Meds unique
- Henry Meds sells compounded oral tirzepatide tablets, updated September 30, 2026.
- Henry Meds bundles provider visits, medication, shipping, and supplies into monthly pricing.
- Henry Meds operates without long-term contracts, with cancellation anytime messaging.
Help us improve and share your feedback! Did you find this helpful?